ClinicalTrials.gg
CompletedNCT06063356Updated Nov 9, 2026

Effects of Dextrose Prolotherapy in Patients With Knee Osteoarthritis

An interventional study of Intra-articular and extra-articular Dextrose Prolotherapy injection and Intra-articular and extra-articular Saline injection in Knee Osteoarthritis, sponsored by Istanbul University. Completed at 1 site in Turkey (Türkiye). Open to female participants aged 40 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-11-09.

Sponsored by Istanbul University · Not applicable, Interventional, and Treatment

How we know

Updated Nov 9, 2026Now CompletedPrimary completion moved+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
66
Allocation
Randomized
Ages
40 Years to 65 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 11 studies in Osteoarthritis, Knee by Istanbul University — 3 open to participants now, 3 under way, none of them phase 3. Osteoarthritis, Knee · Istanbul University.

Started
2023
with 3 others
No phase
9 of 11
2 open now
Registered
7th of 11
by date

Among the 11 studies in Osteoarthritis, Knee by Istanbul University, this one is one of 4 that started in 2023, is one of 9 with no phase, and was the 7th registered.

Osteoarthritis, Knee

3,297 studies on the registry are indexed under Osteoarthritis, Knee; 623 are open to participants now.

Browse Osteoarthritis, Knee studies →

Open to participants now

3 of the 11 studies in Osteoarthritis, Knee by Istanbul University are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

Who these studies take

Of the 384 Osteoarthritis, Knee studies recruiting now, 178 (46%) set no upper age limit and 113 (29%) stop at 75 or younger; 19 take children under 18; 39 take healthy volunteers.

This study: 40 Years to 65 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 11 studies in Osteoarthritis, Knee by Istanbul University, or all of them as a file.
02

Study summary

In this prospective, randomized, controlled, double-blinded study, we aimed to evaluate the effects of Dextrose Prolotherapy injections in patients with chronic knee osteoarthritis.

Read the detailed description

Patients admitted to Istanbul University, Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation Outpatient Clinic with a diagnosis of knee osteoarthritis and who meet the inclusion criteria will be included in the study. Patients will be informed verbally and in writing about the purpose, duration and method of the study and will be asked to sign an "Informed Consent Form" after their consent is obtained.

In our study, the investigators aimed to evaluate the effects of dextrose prolotherapy injections in patients with chronic knee osteoarthritis. The duration of the study was determined as 8 months and it was planned to include 33 patients for each group to be randomized by computer program according to the order of application and 66 patients in total.

Patients who meet the inclusion and exclusion criteria will be randomized into 2 groups and the first group will receive Dextrose Prolotherapy and home exercise program and the second group will receive saline injection and home exercise program.

After the application, patients will be questioned in terms of side effects and complications.

History and demographic characteristics such as age, gender, height, weight, marital status, educational level and occupation will be questioned, and medical history such as history of comorbidities and treatment approaches will be determined. In the physical examination, knee tests (ROM measurements, ligament tests, meniscus tests, tests for osteoarthritis) will be performed and TUG (Timed Up and Go) Test will be evaluated. Direct knee radiographs will be evaluated according to Kellgren-Lawrence Gonarthrosis Staging. The average and maximum level of pain during activity, at rest and at night will be questioned with the Visual Analog Scale (0-10 points). WOMAC pain score and WOMAC total scores will be questioned. Isokinetic muscle strength and proprioception will be evaluated with Biodex Isokinetic Dynamometer in our clinic. Functional status will be evaluated with Euro-Qol Quality of Life Scale. The evaluations will be performed by the researcher who is blinded to the applications.

Assessments will be made before treatment, 1 month, 3 months and 6 months after treatment.

03

Conditions studied

  • Knee Osteoarthritis
04

Who can participate

Ages eligible
40 Years to 65 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Unilateral or bilateral symptomatic knee pain resistant to conservative treatment for at least three months
  • Presence of Kellgren-Lawrence stage 2-3 osteoarthritis on current anterior-posterior knee radiographs
  • 40-65 years of age
  • Functional ambulation scale stage 4-5

Exclusion criteria

Exclusion Criteria:

  • Kellgren-Lawrence stage 1 or stage 4 osteoarthritis on current anterior-posterior knee radiographs
  • Intra-articular knee injection within the last six months
  • History of severe trauma to the knee within the past six months
  • Concomitant severe meniscus or ligament injury, surgery applied to the knee area
  • Presence of severe effusion, inflammatory joint disease, infection, hematological and oncological disease in the knee.
  • Having a bleeding disorder and / or using warfarin
  • Patients with less than 11g/dL and count of less than 150,000 platelets per microliter
  • Presence of uncontrolled diabetes mellitus
  • Presence of cardiac or systemic disease that may affect exercise
  • The presence of neurological disease and psychiatric disease such as Parkinson's disease, stroke history that may affect balance
  • ≥35 kg/m²
  • Allergy to local anesthetic
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
66 participants (actual)

Study arms

  • Active comparator
    Dextrose Prolotherapy

    Intra-articular Injection: A total of 5 cc of 25% dextrose solution (4 cc of 30% dextrose + 1 cc of saline) will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique using a sterile injector with a 20 gauge needle tip with ultrasound guidence.

    Procedure: Intra-articular and extra-articular Dextrose Prolotherapy injection · Procedure: Intra-articular and extra-articular Saline injection

  • Active comparator
    Saline

    Intra-articular Injection: Using a sterile syringe with a 20 gauge needle tip, a total of 5 cc of saline will be administered to the patellofemoral joint space in each patient with the same technique using the supero-lateral technique ultrasound guidence.

    Procedure: Intra-articular and extra-articular Dextrose Prolotherapy injection · Procedure: Intra-articular and extra-articular Saline injection

Interventions

  • ProcedureIntra-articular and extra-articular Dextrose Prolotherapy injection

    In the prolotherapy group, 28 patients will receive intra-articular 5 cc 25% dextrose solution (4 cc 30% dextrose + 1 cc saline) and extra-articular 10 cc 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) in 3 sessions.Extra-articular Injection: Using a sterile syringe with a 27 gauge needle tip (Dental), the points previously found and marked with US (medial collateral ligament, lateral collateral ligament, patellar ligament and adhesion sites of coronary ligaments; pes anserine and superior patellar regions) perpendicular to the surface, using peppering technique, a total of 10 cc of 15% dextrose solution (5 cc 30% dextrose + 2.5 cc saline + 2.5 cc 1% lidocaine) will be injected in small volumes (0.5cc-1cc) at each point.Injection applications will be done at weeks 0 - 3 - 6.

  • ProcedureIntra-articular and extra-articular Saline injection

    In the saline group, 28 patients are planned to receive 3 sessions of intra-articular 5 cc saline and extra-articular 10 cc lidocaine-serum physiologic solution (5 cc saline + 5 cc 1% lidocaine).Injection applications will be done at weeks 0 - 3 - 6.

06

What researchers measure

Primary outcomes

  1. Change from baseline pain score at 1-months, 3-months and 6-months

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measures knee pain, stiffness, and physical function. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for the three subscales gives a total WOMAC score. High scores are associated with more pain, stiffness, and poor function, while low scores indicate well-being.

    Time frame: Baseline, 1-month, 3-month, 6-month

Secondary outcomes

  1. Change from baseline stiffness and physical function at 1-months, 3-months and 6-months

    Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) measures knee pain, stiffness, and physical function. The scores for each subscale are summed up, with a possible score range of 0-20 for Pain, 0-8 for Stiffness, and 0-68 for Physical Function. The sum of the scores for the three subscales gives a total WOMAC score. High scores are associated with more pain, stiffness, and poor function, while low scores indicate well-being.

    Time frame: Baseline, 1-month, 3-month, 6-month

  2. Change from baseline activity pain score at 1-months, 3-months and 6-months

    Visual Analogue Scale-Activity pain (0-10 point). Higher scores mean a worse outcome

    Time frame: Baseline, 1-month, 3-month, 6-month

  3. Change from baseline rest pain score at 1-months, 3-months and 6-months

    Visual Analogue Scale-Rest pain (0-10 point). Higher scores mean a worse outcome

    Time frame: Baseline, 1-month, 3-month, 6-month

  4. Change from baseline night pain score at 1-months, 3-months and 6-months

    Visual Analogue Scale-Night pain (0-10 point). Higher scores mean a worse outcome

    Time frame: Baseline, 1-month, 3-month, 6-month

  5. Change from baseline quality of life at 1-months, 3-months and 6-months

    The EuroQOL (EQ-5D-3L) scale is a scale developed to assess health-related quality of life and consists of two parts. The first part describes the health profile in 5 dimensions (mobility, self-care, social life, pain and psychological state). Each dimension includes 3 statements according to the degree of difficulty (1- some problem; 2-moderate; 3-much problem), the second part includes a visual analog scale (VAS) in which respondents rate their current health status from 0 to 100.

    Time frame: Baseline, 1-month, 3-month, 6-month

  6. Change from baseline functional balance at 1-months, 3-months and 6-months

    Timed Up and Go test requires the person to stand up from a standard chair in which they are sitting, walk 3 m at a comfortable speed to the marked place on the floor, turn around, walk backwards to the starting point and return to the sitting position in the chair. The time taken for the person to complete the test is measured in seconds. The timing of the test is related to the function.

    Time frame: Baseline, 1-month, 3-month, 6-month

  7. Change from baseline muscle strength and proprioception at 3-months and 6-months

    Isokinetic muscle strength and proprioception will be evaluated with Biodex Isokinetic Dynamometer

    Time frame: Baseline, 3-month, 6-month

07

Study locations

1 site
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2023 to primary completion in Aug 2024, 12 months.

Of 1,114 non-industry interventional studies with no phase under Osteoarthritis, Knee, half reached primary completion within 18 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 36. This study's 12 months is below that.

Counting every sponsor, half of 1,253 studies reached it within 18 months; a quarter within 8 and three quarters within 36.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 9, 2026: primary completion Apr 2024 → Aug 2024 and completion Jun 2024 → Dec 2024.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2023
First posted
Oct 2, 2023
StartActual
Aug 15, 2023
Primary completionActual
Aug 20, 2024was Apr 2024
CompletionActual
Dec 20, 2024was Jun 2024
Last update
Nov 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 9, 2026
Primary completion
Apr 20, 2024→Aug 20, 2024 (actual)
Nov 9, 2026
Study completion
Jun 20, 2024→Dec 20, 2024 (actual)
Nov 9, 2026
Eligibility
Sex ALL→FEMALE
Nov 9, 2026
Show all 1 update
  1. Nov 9, 2026
    Active, not recruiting→Completed
    Primary completion Apr 20, 2024→Aug 20, 2024 (now actual)
    Study completion Jun 20, 2024→Dec 20, 2024 (now actual)
    Eligibility Sex ALL→FEMALE
    + 5 other changes: verification date, description, design details, arm descriptions and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT06063356
Responsible party
Ekin Ilke Sen (Assistant Professor, Istanbul University) — Principal investigator
First posted
Oct 2, 2023
Start date
Aug 15, 2023
Primary completion
Aug 20, 2024
Completion
Dec 20, 2024
Last update
Nov 9, 2026

Study contacts

Ekin I Sen, Assoc.Prof.
principal investigator · Istanbul University Istanbul Faculty of Medicine, Department of Physical Medicine and Rehabilitation

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion